HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) All Versions of this Article: R500013-JLR200v1 47/2/241    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ridlon, J. M. Articles by Hylemon, P. B. Search for Related Content PubMed PubMed Citation Articles by Ridlon, J. M. Articles by Hylemon, P. B. Social Bookmarking                      What's this?

Journal of Lipid Research, Vol. 47, 241-259, February 2006
Copyright © 2006 by American Society for Biochemistry and Molecular Biology

Review

Bile salt biotransformations by human intestinal bacteria

Jason M. Ridlon, Dae-Joong Kang and Phillip B. Hylemon¹

Department of Microbiology/Immunology, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA

Published, JLR Papers in Press, November 18, 2005.

¹ To whom correspondence should be addressed. e-mail: hylemon{at}hsc.vcu.edu

	ABSTRACT

TOP ABSTRACT INTRODUCTION THE ENTEROHEPATIC CIRCULATION OF... DECONJUGATION OF BILE SALTS MICROBIAL BILE ACID... THE BIOCHEMISTRY AND MOLECULAR... SECONDARY BILE ACIDS AND... DISCUSSION REFERENCES

 
Secondary bile acids, produced solely by intestinal bacteria, can accumulate to high levels in the enterohepatic circulation of some individuals and may contribute to the pathogenesis of colon cancer, gallstones, and other gastrointestinal (GI) diseases. Bile salt hydrolysis and hydroxy group dehydrogenation reactions are carried out by a broad spectrum of intestinal anaerobic bacteria, whereas bile acid 7-dehydroxylation appears restricted to a limited number of intestinal anaerobes representing a small fraction of the total colonic flora. Microbial enzymes modifying bile salts differ between species with respect to pH optima, enzyme kinetics, substrate specificity, cellular location, and possibly physiological function. Crystallization, site-directed mutagenesis, and comparisons of protein secondary structure have provided insight into the mechanisms of several bile acid-biotransforming enzymatic reactions. Molecular cloning of genes encoding bile salt-modifying enzymes has facilitated the understanding of the genetic organization of these pathways and is a means of developing probes for the detection of bile salt-modifying bacteria. The potential exists for altering the bile acid pool by targeting key enzymes in the 7/ß-dehydroxylation pathway through the development of pharmaceuticals or sequestering bile acids biologically in probiotic bacteria, which may result in their effective removal from the host after excretion.

Supplementary key words bile acids • deoxycholic acid • 7-dehydroxylation • gallstone disease • colon cancer • bile salt hydrolase • probiotics • hydroxysteroid dehydrogenase • hydrogen sulfide

Abbreviations: bai, bile acid-inducible; BSH, bile salt hydrolase; CA, cholic acid; CBAH-1, conjugated bile acid hydrolase from C. perfringens; CDCA, chenodeoxycholic acid; DCA, deoxycholic acid; GDCA, glycodeoxycholate; HSDH, hydroxysteroid dehydrogenase; LCA, lithocholic acid; TDCA, taurodeoxycholate; UDCA, ursodeoxycholic acid

	INTRODUCTION

TOP ABSTRACT INTRODUCTION THE ENTEROHEPATIC CIRCULATION OF... DECONJUGATION OF BILE SALTS MICROBIAL BILE ACID... THE BIOCHEMISTRY AND MOLECULAR... SECONDARY BILE ACIDS AND... DISCUSSION REFERENCES

 
The human large intestine harbors a complex microbial flora (1). Bacterial density in the human colon is among the highest found in nature, approaching 10¹² bacteria/g wet weight of feces (2, 3). In contrast, the host suppresses significant bacterial colonization of the small intestine by a variety of mechanisms, including rapid transit times, antimicrobial peptides, proteolytic enzymes, and bile (4). Failure of these mechanisms leads to bacterial overgrowth of the small intestine, resulting in malabsorption as bacteria compete with the host for nutrients. Under normal conditions, bacterial fermentation in the colon represents an important salvage mechanism. Complex carbohydrates, which are intrinsically indigestible or which escape digestion and absorption in the proximal gut, are fermented by colonic bacteria to yield short-chain fatty acids. It has been estimated that these short-chain fatty acids constitute 3–9% of our daily caloric intake (4). Colonic bacteria also contribute to the salvage of bile salts that escape active transport in the distal ileum. The major bile salt modifications in the human large intestine include deconjugation, oxidation of hydroxy groups at C-3, C-7, and C-12, and 7/ß-dehydroxylation (Fig. 1). Deconjugation and 7/ß-dehydroxylation of bile salts increases their hydrophobicity and their Pk_a, thereby permitting their recovery via passive absorption across the colonic epithelium. However, the increased hydrophobicity of the transformed bile salts also is associated with increased toxic and metabolic effects. High concentrations of secondary bile acids in feces, blood, and bile have been linked to the pathogenesis of cholesterol gallstone disease and colon cancer (5). We present here a current review of the microbiology of bile acid metabolism in the human GI tract, focusing on understanding the biochemical mechanisms and physiological consequences of such metabolism on both the bacterium and the human host.

View larger version (23K): [in this window] [in a new window]   Fig. 1. Bacterial bile salt-biotransforming reactions in the human intestinal tract. Hydroxy group carbons of cholate are numbered and the AB rings are identified. The 3, 7, and 12 carbons of cholic acid (CA) are numbered. Nomenclature is that of Hofmann et al. (160). BSH, bile salt hydrolase; HSDH, hydroxysteroid dehydrogenase.

	THE ENTEROHEPATIC CIRCULATION OF BILE ACIDS

TOP ABSTRACT INTRODUCTION THE ENTEROHEPATIC CIRCULATION OF... DECONJUGATION OF BILE SALTS MICROBIAL BILE ACID... THE BIOCHEMISTRY AND MOLECULAR... SECONDARY BILE ACIDS AND... DISCUSSION REFERENCES

View larger version (69K): [in this window] [in a new window]   Fig. 2. Anatomy, physiology, and microbiology of the gastrointestinal tract. Large arrows denote the enterohepatic circulation of bile acids, which begins with contraction of the gallbladder, releasing bile into the duodenum. Small arrows denote the passive absorption of bile acids that escape active transport. * Secondary bile acids produced by 7-dehydroxylation are passively absorbed in the large intestine and returned to the liver (see Fig 3). The genera of predominant bacteria isolated from each region of the lower gastrointestinal tract are listed.

View larger version (27K): [in this window] [in a new window]   Fig. 3. Composition of bile acids in the gallbladder and feces of healthy individuals. "Other" bile acids refer to oxo- and 3ß-hydroxy derivatives of secondary bile acids. Values were derived from published sources (6, 93, 161, 162). CDCA, chenodeoxycholic acid; DCA, deoxycholic acid; LCA, lithocholic acid; UDCA, ursodeoxycholic acid.

	DECONJUGATION OF BILE SALTS

TOP ABSTRACT INTRODUCTION THE ENTEROHEPATIC CIRCULATION OF... DECONJUGATION OF BILE SALTS MICROBIAL BILE ACID... THE BIOCHEMISTRY AND MOLECULAR... SECONDARY BILE ACIDS AND... DISCUSSION REFERENCES

View larger version (145K): [in this window] [in a new window]   Fig. 4. Multiple sequence alignment of cholylglycine hydrolases. Protein sequences were obtained from the National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov/). Alignments were made with the ClustalW program (http://www.ebi.ac.uk/clustalw/) using the GONNET 250 matrix. Residues highlighted in yellow are predicted active site amino acids based on the crystal structure of the BSH from C. perfringens (11) as well as on site-directed mutagenesis and biochemical data (10, 12–14). Residues highlighted in gray correspond to residues involved in substrate binding in the BSH from C. perfringens (11). The secondary structural elements, which are based on the conjugated bile acid hydrolase from C. perfringens (CBAH-1) crystal structure, are shown above the alignment. The and ß designations of Lactobacillus johnsonii refer to the two isoforms of the genes found in this bacterium.

Benefits of BSHs to the bacterium
BSHs appear to enhance the bacterial colonization of the lower gastrointestinal tract of higher mammals. The physiological advantages of BSHs are not fully understood and may vary between bacterial species and genera. It has been hypothesized that deconjugation may be a mechanism of the detoxification of bile salts. De Smet et al. (26) observed significantly higher rates of deconjugation of glycodeoxycholate (GDCA) over TDCA in La. plantarum. Mutants lacking functional BSH (bsh^–) exhibited pH- and concentration-dependent toxicity of GDCA compared with wild-type cells; this effect was not demonstrated with TDCA. De Smet et al. (26) hypothesized that the difference in dissociation constants between GDCA and TDCA resulted in the collapse of cellular proton motive force by intracellular deprotonation with the glycine conjugate. The presence of a functional BSH results in the intracellular accumulation of free bile acids, which become protonated in a stoichiometric manner, decreasing energy-dependent H⁺-ATPase-driven proton efflux. BSHs from human intestinal lactobacilli generally have higher affinity for glycine conjugates (26–29). This observation may lend weight to the hypothesis of De Smet et al. (26), or the higher affinity of BSHs for glycine conjugates may have evolved because glycine conjugates are generally higher in proportion (3:1) than taurine conjugates in human bile (6). Tannock, Dashkevicz, and Feighner (30) argued against the hypothesis of deconjugation as a means of detoxification in lactobacilli, because free bile acids are more cytotoxic than their conjugates. However, when the free bile acids become 7-dehydroxylated by other intestinal bacteria in vivo, the resultant secondary bile acids tend to precipitate (with the extent depending on luminal pH) and bind to insoluble fiber, or they may be absorbed through the colonic membrane and may exist in low concentrations in the bacterium's microenvironment. Therefore, additional studies comparing various characteristics of bsh knockouts with their isogenic parent strain will be needed to determine the function of deconjugation in Lactobacillus species.

Strategies to resist bile salt toxicity have been observed in pathogens that colonize the intestinal tract (31–33). Recently, a BSH from Li. monocytogenes was shown to be a novel virulence factor (21). Comparative genome analysis revealed the absence of a bsh gene in the closely related nonvirulent Li. innocua (20). The bsh gene is positively regulated by PrfA, which is a transcriptional activator of numerous virulence genes in Li. monocytogenes. Deletion of the bsh gene results in decreased resistance to bile salts and significantly reduced infectivity in vivo. These results demonstrate the importance of BSH activity for survival in vivo and infection in the intestinal and hepatic phases of listeriosis. The mechanism by which BSH activity in Li. monocytogenes enhances survival and virulence is currently unknown.

Deconjugation may provide a means of obtaining cellular carbon, nitrogen, and sulfur for some bacterial species. This has been demonstrated in bacteroides (34) and is suggested in Bi. longum (10). In fact, the bsh gene from Bi. longum is cotranscribed with the gene encoding glutamine synthetase adenylyltransferase (glnE), a component of the nitrogen regulation cascade (10). In this regard, hydrolysis of the conjugated bile acid may provide amino nitrogen, providing a possible explanation for the coordinated regulation of these seemingly physiologically unrelated genes (10). Taurine utilization is also widespread and can serve as an energy source under both aerobic and anaerobic conditions (35). Glycine can be used as an energy source by certain clostridia by the Stickland reaction (36). The Stickland reaction is a form of amino acid fermentation in which one amino acid donates electrons that are accepted by another amino acid distinct from the electron donor. Another hypothesis suggests that BSHs are detergent shock proteins enabling survival during stress (37). De Smet et al. (26) found no evidence for this in lactobacilli after growth with various detergents.

The widespread distribution of BSHs across Gram-negative and Gram-positive intestinal bacteria coupled with a wide range of substrate specificities, genetic regulation, and the occurrence of multiple isoforms in certain strains have created conflicting reports regarding the physiological benefit to the bacterium in hydrolyzing bile acid conjugates. Determining the mechanism(s) by which BSHs aid bacteria in the colonization of the mammalian intestine will be of great interest, especially with regard to bacterial pathogenesis.

Taurine, hydrogen sulfide production, and colon cancer
The bile acid conjugates glycine and taurine serve as substrates in microbial metabolism. Unlike glycine, taurine contains a sulfonic acid moiety that is reduced and dissimilated to hydrogen sulfide after deconjugation (38, 39). Hydrogen sulfide is highly toxic and has been shown to increase colonocyte turnover (40). Activation and upregulation of the extracellular signal-regulated kinase 1 and 2 (ERK1/2) signaling pathway has been suggested as a possible mechanism for sulfide-induced colonocyte proliferation (41). Hydrogen sulfide also inhibits butyrate metabolism in colonocytes, a key nutrient and regulator of cell turnover in the gut (40). Levitt et al. (42) demonstrated that colonocytes have evolved a highly efficient mechanism to detoxify volatile reduced sulfides through oxidation to thiosulfate. Defects in this detoxification system are suggested to play a role in the pathogenesis of ulcerative colitis, a known risk factor for colon cancer (42, 43). Recently, sulfide was implicated in preventing apoptosis in the adenocarcinoma cell line HCT116 after exposure of cells to ß-phenylethyl isothiocyanate, a phytochemical found in cruciferous vegetables, which has been shown to prevent colon carcinogenesis (44, 45).

A diet high in meat has been shown to significantly increase both the levels of taurine conjugation to bile acids (46, 47) and the production of hydrogen sulfide in the colon (48). A relationship exists between the generation of hydrogen sulfide in the colon and chronic GI illness, such as inflammatory bowel disease and colon cancer (5, 49). Populations such as native black Africans with low incidence of colon cancer consume low-meat diets (50). Native black Africans also have low ratios of taurine to glycine conjugation (1:9) and low hydrogen sulfide production compared with populations consuming a "Western diet" (46, 47). In human fecal slurries obtained from individuals consuming a Western diet, taurine addition generated some of the highest sulfide levels of any organic or inorganic sulfur source added (43). Taurine addition to a coculture of a species of bacteroides and an unidentified 7-dehydroxylating bacterium resulted in significant sulfide production, which stimulated increased rates of DCA production (34).

Although the extent to which taurine metabolism contributes to total colonic sulfide production has yet to be established, several key points have been made: 1) the extent of taurine conjugation in the bile acid pool is largely affected by diet; 2) the same dietary factors that increase taurine conjugation are hypothesized to increase colon cancer risk; 3) taurine metabolism by intestinal bacteria results in hydrogen sulfide generation; 4) sulfide generation is linked to the carcinogenesis process through enhanced cell proliferation, inhibition of butyrate metabolism, and activation of cell signaling pathways; and 5) sulfide generation may enhance DCA formation in the gut through stimulation of the microbial bile acid 7-dehydroxylation pathway.

	MICROBIAL BILE ACID HYDROXYSTEROID DEHYDROGENASE(S)

TOP ABSTRACT INTRODUCTION THE ENTEROHEPATIC CIRCULATION OF... DECONJUGATION OF BILE SALTS MICROBIAL BILE ACID... THE BIOCHEMISTRY AND MOLECULAR... SECONDARY BILE ACIDS AND... DISCUSSION REFERENCES

 
Oxidation and epimerization
Oxidation and epimerization of the 3-, 7-, and 12-hydroxy groups of bile acids in the GI tract are carried out by hydroxysteroid dehydrogenase (HSDH) expressed by intestinal bacteria (Fig. 1). Epimerization of bile acid hydroxy groups is the reversible change in stereochemistry from to ß configuration (or vise versa) with the generation of a stable oxo-bile acid intermediate. Epimerization requires the concerted effort of two position-specific, stereochemically distinct HSDHs of intraspecies or interspecies origin. For example, the presence of both 7- and 7ß-HSDH in C. absonum allows epimerization by a single bacterium (51), whereas epimerization also can be achieved in cocultures of intestinal bacteria, one possessing 7-HSDH and the other 7ß-HSDH (52, 53).

The extent of the reversible oxidation and reduction of bile acid hydroxy groups by HSDH depends in part on the redox potential of the environment. Addition of oxygen to the culture medium increases the accumulation of oxo-bile acids (51). Generation of oxo-bile acids may be more favorable under the higher redox potentials found on the mucosal surface (4), whereas reduction of oxo-bile acids may be more favorable under the low redox potential (–200 to –300 mV) in the large intestinal lumen. Thus, although the redox potential of the colon is net reductive, microenvironments at the mucosa may provide oxidizing conditions favorable for certain microbial reactions. HSDHs differ in their reductive and oxidative pH optima, NAD(H) or NADP(H) requirements, molecular weight, and gene regulation (Table 2).

3- and 3ß-HSDHs

Pyridine nucleotide cofactor requirements differ between 3/ß-HSDHs. 3-HSDHs require NAD(H), with the exception of the enzyme purified from C. perfringens, which uses NADP(H), and that purified from C. scindens, which can use either NAD(H) or NADP(H) (54, 56–58, 61). 3ß-HSDHs have been shown to preferentially require NADP(H), with the exception of C. innocuum, which uses NAD(H) (62–64). Dihydroxy bile acids [DCA, CDCA, and ursodeoxycholic acid (UDCA)] are generally better substrates than trihydroxy bile acids (CA) (62, 65).

3/ß-HSDHs characterized to date are constitutively expressed with the exception of those from C. scindens and C. hiranonis, which are induced by the primary bile acids CA and CDCA. In fact, three copies of 3-HSDH genes (the bile acid-inducible genes baiA1, baiA2, and baiA3) have been identified from C. scindens (66, 67), and baiA1 has been expressed in Escherichia coli and characterized (58). The baiA gene products are unique among 3/ß-HSDHs as a result of their high specificity toward CA-CoA and CDCA-CoA conjugates and relatively low activity toward free bile acids (58).

7- and 7ß-HSDHs
7/ß-HSDHs catalyze the reversible, stereospecific oxidation/reduction of the 7- and 7ß-hydroxyl groups of bile acids. Although 7/ß-HSDHs are common among intestinal bacteria, the extent of 7/ß-dehydrogenation in the intestine, or in mixed fecal suspensions, is difficult to interpret because of the competing, and irreversible, 7/ß-dehydroxylation of bile acids (see below) (68).

7/ß-HSDHs are widespread among the bacteroides and clostridia as well as in E. coli and Ruminococcus species (Table 2) (54, 64, 69–74). In addition, several intestinal clostridia express both 7- and 7ß-HSDHs and have been shown to epimerize the 7/ß-hydroxy group (75, 76–78). 7/ß-HSDHs have been partially purified from intestinal bacteria, including Ba. fragilis (71, 79), Ba. thetaiotaomicron (74), C. scindens (80), C. sordellii (70), and E. coli (73), as well as from the soil isolates Xanthomonas maltophilia (81), C. absonum (82), and C. bifermentans (83). Interestingly, several intestinal bacteria with 7/ß-HSDH activity also possess BSH, including Ba. fragilis (25), C. sordellii (70), C. perfringens (84), and C. innocuum (63), as well as the soil isolate C. bifermentans (83).

7-HSDHs generally use NADP(H) as a cofactor, with the exception of E. coli (85) and Ba. thetaiotaomicron (74). C. bifermentans, C. absonum, and Ba. fragilis 7-HSDHs can use either NAD(H) or NADP(H) as a cofactor (76, 79, 83). 7ß-HSDH enzymes characterized to date use NADP(H) as a cofactor (53, 62, 75, 76). 7/ß-HSDH enzymes have higher affinity for dihydroxy bile acids (CDCA and 7-oxo-LCA) than for trihydroxy bile acids (CA and 7-oxo-DCA). C. limosum cell extracts use both free and conjugated bile acids, whereas whole cells only oxidize free bile acids (75, 86). This is attributable to the intracellular location of the 7-HSDH and the inability of the organism to take up a conjugated bile salt. The genes encoding 7-HSDHs have been cloned from E. coli (73), C. scindens (69), and C. sordellii (70). Sequence similarity suggests that these enzymes belong to the short-chain polyol dehydrogenase family. Regulation of 7/ß-HSDH expression is generally growth phase-dependent and inducible by bile acid substrates (Table 2). C. scindens and E. coli constitutively express 7-HSDHs and are noninducible (69, 85). Unexpectedly, the nonsubstrate DCA can induce 7-HSDH expression in C. absonum and C. sordellii, although the reason for this induction remains unclear (70, 76). Macdonald, White, and Hylemon (82) observed the expression of five soluble and two membrane polypeptides upon exposure of C. absonum to DCA and CDCA in the culture medium, although the functions of these additional polypeptides have not been determined.

Crystal structures of the E. coli 7-HSDH binary and ternary complexes have been solved and a mechanism for 7-dehydrogenation proposed (Fig. 5) (87). Binding of 7-hydroxy bile acids elicits major conformational changes at the substrate binding loop and C-terminal domain. A two-step mechanism is proposed in which Tyr159 acts as a catalytic base removing the C-7 hydroxy hydrogen. Hydrogen bonding by serine 146 (Ser146) is hypothesized to stabilize the intermediate. Regeneration of the catalyst occurs through the transfer of the acquired hydride from the phenolic group at Tyr159 to lysine 163 (Lys163) to position 4 of NAD⁺. Lys163 serves two important roles: anchoring NAD⁺ through bifurcated hydrogen bonding, and indirect hydride transfer from Tyr159 to position 4 of NAD⁺ (87). Site-directed mutagenesis confirmed the role of these amino acids in 7-HSDH catalysis (88). Analysis of the 7-oxo-GLCA bile acid substrate/enzyme complex revealed tight binding of the sterol with loose association for the glycine conjugate. Binding of glycine and taurine conjugates of CDCA was not significantly different from that of the free bile acid (87).

View larger version (18K): [in this window] [in a new window]   Fig. 5. Proposed catalytic mechanism of bile acid 7-dehydrogenation based on the crystal structure and site-directed mutagenesis of active site amino acids of the 7-dehydrogenation from E. coli. See text for a description of catalysis. Reprinted with permission from Tanaka et al. (87). Copyright © 1996 American Chemical Society.

12- and 12ß-HSDHs

Benefits of bile acid hydroxysteroid oxidoreductases to the bacterium
The oxidation of bile acid hydroxyl groups generates reducing equivalents for cellular biosynthetic reactions and possibly electron transport phosphorylation. Bile acid dehydrogenation is hypothesized to generate energy in Ba. thetaiotaomicron (74). Sherod and Hylemon (74) suggested that reduced pyridine nucleotides generated from 7-hydroxy oxidation serve to generate ATP via a cytochrome-linked electron transport chain in the presence of electron acceptors (i.e., fumarate).

Bile acids are potent antimicrobial agents provided that the proper concentration and proportion of hydrophobic bile acids (CDCA, LCA, and DCA) are present (95). Alteration of hydroxy group stereochemistry has a marked influence on the physiochemical properties of bile acids (96, 97). The epimerization of the 7-hydoxy group of CDCA decreases the hydrophobicity and toxicity of the bile acid (97). Macdonald, White, and Hylemon (82) observed that C. absonum grew on plates containing 1 mM UDCA, although it was unable to grow on plates containing 1 mM CDCA. Furthermore, when cultured in the presence of 7-oxo-bile acids, only low concentrations of CA and CDCA were formed, whereas the majority of 7-oxo-bile acids were reduced to 7-epicholic acid and UDCA, respectively, by log-phase C. absonum (51). UDCA has also been shown to act as a repressor of 7/ß-HSDH production in C. absonum, suggesting that UDCA is an end product (76). The enzyme also displays markedly higher affinity for CDCA than for CA, the former being more toxic. In summary, dehydrogenation may serve functions related to energy generation as well as attempts to maintain low concentrations of more hydrophobic bile acids in the bacterium's microenvironment.

Interplay between HSDH enzymes in human liver and intestinal bacteria
The coevolution between host and gut flora is evident when observing the interplay between liver and bacterial biotransforming reactions. The liver synthesizes bile acids in which the hydroxy groups are in the orientation. In the -hydroxy orientation, one face of the molecule is hydrophobic and the other side is hydrophilic. This translates to efficient solubilization of lipid molecules through the formation of mixed micelles capable of efficient emulsification while remaining soluble in aqueous environments. Generation of ß-hydroxy bile acids by microbial enzymes alters the efficiency of micelle formation as a result of hydrophilic groups on both faces of the sterol molecule. The differences observed between the composition of bile acids in serum and bile are a result of the continual interplay between liver and bacterial enzymes. Exposure of bile salts to intestinal bacteria results in 50% of bile acids requiring reconjugation and low levels of bile acids returned to the liver in the 3ß-hydroxy orientation (98). Without a means of epimerizing bile acid hydroxy groups in the human liver, ß-hydroxy bile acids would accumulate in the bile acid pool. Interestingly, the liver seems to "allow" the accumulation of UDCA (7ß-hydroxy) in the biliary pool, as in the case of therapeutic administration of CDCA (99). The protective effects of UDCA observed in clinical studies (100) as well as cell culture studies (97, 101) may provide an evolutionary explanation for this phenomenon.

	THE BIOCHEMISTRY AND MOLECULAR BIOLOGY OF BILE ACID 7/ß-DEHYDROXYLATION

TOP ABSTRACT INTRODUCTION THE ENTEROHEPATIC CIRCULATION OF... DECONJUGATION OF BILE SALTS MICROBIAL BILE ACID... THE BIOCHEMISTRY AND MOLECULAR... SECONDARY BILE ACIDS AND... DISCUSSION REFERENCES

 
Introduction
Secondary bile acids (DCA and LCA) predominate in human feces (Fig. 3). Therefore, 7-dehydroxylation is the most quantitatively important bacterial bile salt biotransformation in the human colon. The rapid rate of conversion of primary to secondary bile acids is surprising given current estimates that this metabolic pathway is found in 0.0001% of total colonic flora (102–104). Human intestinal bacteria capable of bile acid 7-dehydroxylation have been isolated (104, 105), and 16S rDNA phylogenetic analysis has led to their classification to the genus Clostridium (106–108).

Unlike bile acid oxidation and epimerization, 7/ß-dehydroxylation appears restricted to free bile acids. Removal of glycine/taurine bile acid conjugates via BSH enzymes is thus a prerequisite for 7/ß-dehydroxylation by intestinal bacteria (109–112). Some intestinal bacteria are capable of both 7/ß-dehydroxylating activities (113), whereas 7ß-dehydroxylation activity is absent in other intestinal 7-dehydroxylating bacteria (113). Epimerization of UDCA (7ß-hydroxy) to CDCA (7-hydroxy) via 7ß-HSDHs produced by members of the gut flora results in subsequent 7-dehydroxylation. In this regard, it appears that the presence of 7ß-dehydroxylation activity is more of a luxury than a necessity.

Elucidating the bile acid 7/ß-dehydroxylation pathway
Samuelsson (114) administered [6-³H,6ß-³H,8ß-³H][24-¹⁴C]CA to bile duct-cannulated rabbits and rats. Analysis of the products recovered after exposure to intestinal bacteria revealed a differential loss of the 6ß-³H during 7-dehydroxylation of CA. Previous work showed complete retention of the 7ß-³H in [7ß-³H][24-¹⁴C]CA during 7-dehydroxylation in the rat intestine (115, 116). These data led Samuelsson (114) to propose a mechanism for CA 7-dehydroxylation involving two steps: diaxial trans-elimination of the 7-hydroxy group and 6ß-hydrogen atom, followed by reduction through trans-hydrogenation of the 6ß and 7 positions of the cholen-6-oic acid intermediate forming DCA. Björkhem et al. (117) showed the formation of a 3-dehydro-4-cholenoic acid intermediate after the differential loss of the 5ßH in vitro and in vivo using [3ß-³H][24¹⁴C]CA and [5ß-³H]24¹⁴C]CA. Hylemon et al. (118) subsequently observed the accumulation of multiple bile acid intermediates in cell extracts of C. scindens induced by CA (Fig. 6). These radiolabeled CA intermediates were identified by mass spectrometry, then chemically synthesized and added to cell extracts of CA-induced C. scindens. Each 24[¹⁴C]CA intermediate was converted to 24¹⁴C]DCA in cell extracts prepared from CA-induced cultures of C. scindens. These observations suggested that the 7-dehydroxylation mechanism was more complex than the two-step mechanism proposed by Samuelsson (114). Furthermore, these data demonstrated that bile acid 7-dehydroxylation was a multistep pathway in C. scindens and suggested the presence of multiple bai genes.

View larger version (85K): [in this window] [in a new window]   Fig. 6. Accumulation of [24-14C]CA intermediates during 7-dehydroxylation in cell extracts of C. scindens VPI 12708. Cell extracts were prepared from either CA-induced (I) or control (C) cells. This figure was modified from Hylemon et al. (118). Copyright © 1992 American Society for Biochemistry and Molecular Biology, Inc.

View larger version (18K): [in this window] [in a new window]   Fig. 7. Gene organization of the bile acid-inducible (bai) 7/ß-dehydroxylation operons characterized in C. scindens VPI 12708. P indicates the promoter region.

View larger version (55K): [in this window] [in a new window]   Fig. 8. Proposed bile acid 7/ß-dehydroxylation pathways in C. scindens VPI 12708 for CDCA and UDCA. Reaction steps in brackets indicate enzymatic steps for CDCA and UDCA intermediates. For simplicity, only CDCA intermediates are shown for the general 7-dehydroxylation pathway. The baiCD and baiE gene products are proposed to encode stereospecific enzymes for 7-hydroxy bile acids. The baiH and baiI gene products are proposed to encode stereospecific enzymes for 7ß-hydroxy bile acids. The baiF gene product has bile acid-CoA hydrolase activity but is hypothesized to encode a bile acid CoA transferase (see text).

bai genes: a regulon for 7/ß-dehydroxylation

After transport, ligation to CoA is the first step in activating CA and CDCA for 7-dehydroxylation, as several subsequent enzymatic steps are specific for CoA conjugates. The baiB gene was shown to encode a 58 kDa bile acid CoA ligase (125). CoA ligation is ATP-, CoA-, and Mg²⁺-dependent and also requires a free carboxyl group on C₂₄ bile acids (125). CoA ligation may function both to sterically hinder the constitutive 7-HSDHs, committing the bile acid to 7-dehydroxylation, and to trap the bile acid inside the cell.

The 3-hydroxy group is oxidized after CoA ligation. Oxidation of the 3-hydroxy group inhibits 7-hydroxy group dehydrogenation, favoring 7-dehydroxylation over constitutively expressed 7-HSDHs in C. scindens (58, 80). The baiA gene products encode 27 kDa polypeptides that have significant similarity with the short-chain alcohol/polyol dehydrogenase gene family (58, 124). Amino acid multiple sequence alignment and comparison between baiA gene products and other members of the short-chain alcohol dehydrogenase family revealed a possible NAD(P) binding site and catalytic active site (58). Three baiA genes have been cloned from C. scindens; the baiA1 and baiA3 genes are monocistronic, whereas the baiA2 gene is part of the polycistronic bai operon (66, 67, 124). The baiA genes from C. scindens were cloned in E. coli and shown to encode 3-HSDHs (58). The enzymes only recognize bile acid CoA conjugates and can use either NAD⁺ or NADP⁺ as electron acceptors (58). Interestingly, the different 3-HSDHs of C. scindens share 92% amino acid sequence identity with one another, suggesting gene duplication. The physiological importance of multiple baiA genes remains unclear.

The baiCD gene from C. scindens has been cloned and expressed in E. coli and was recently demonstrated to encode a steroid oxidoreductase specific for the CoA conjugates of 3-dehydro-4-cholenoic acid and 3-dehydro-4-chenodeoxycholenoic acid (Fig. 8) (P. B. Hylemon et al., unpublished data). The 70 kDa enzyme requires FMN and NAD⁺ or NADP⁺ for activity and shows stereospecificity toward 7-hydroxy bile acids. The BaiCD polypeptide shows considerable amino acid sequence identity with the Old Yellow Enzyme family, a putative NADH oxidase from Li. monocytogenes, several 2,4-dienoyl CoA reductases, and baiH from C. scindens (121, 129). The baiH gene encodes a 72 kDa polypeptide containing 661 amino acids (121). The BaiH protein exists as a homotrimer with NADH:flavin oxidoreductase activity (121). The baiH gene has been subcloned into E. coli, purified, and shown to contain 1 mol of FAD, 2 mol of iron, and 1 mol of copper per mole polypeptide subunit (129). The baiH gene product from C. scindens was recently determined to encode a steroid oxidoreductase specific for CoA conjugates of 3-dehydro-4-ursodeoxycholenoic acid and 3-dehydro-4-epicholenoic acid (Fig. 8) (P. B. Hylemon et al., unpublished data). Oxidation of CA-CoA, CDCA-CoA, and UDCA-CoA to their respective 3-dehydro-4-bile acid CoA conjugates appears to make the bile acid chemically labile for 7/ß-dehydration.

The baiF gene encodes a 47.5 kDa polypeptide containing 426 amino acids that was shown to have bile acid CoA hydrolase activity (122, 130). However, baiF is hypothesized to encode a CoA transferase because of energy conservation (Fig. 8) and homology to the type III family of CoA transferases (131). The first few cycles of 7-dehydroxylation would require ATP hydrolysis (Fig. 8), although ATP-independent recycling of the thioesterase intermediates via transfer of CoA from 3-dehydro-4-cholenoic acid to CA, 3-dehydro-4-chenodeoxycholenoic acid to CDCA, or 3-dehydro-4-ursodeoxycholenoic acid to UDCA by the baiF would significantly conserve energy. However, this hypothesis remains to be tested.

7-Dehydration of 3-dehydro-4-cholenoic acid and 3-dehydro-4-chenodeoxycholenoic acid results in the generation of a conjugated double bond in rings A and B, forming stable 3-dehydro-4,6-deoxycholdienoic acid and 3-dehydro-4,6-lithocholdienoic acid intermediates, respectively. The 7-dehydration step results in the largest calculated energy change (–9.4 kcal/mol) of any reaction in this pathway, and the reverse reaction was not detected in vitro (128). The 19.5 kDa bile acid 7-dehydratase is encoded by the baiE gene (128). This enzyme showed no activity with 3-dehydro-4-ursodeoxycholenoic acid (128). The baiE gene product was modeled on the crystal structure of the protein homologs (secondary structure) ketosteroid isomerase and scytalone dehydratase (Fig. 9) (K. Woodford et al., unpublished data). The putative active site/binding pocket is shown in Figure 10. A catalytic mechanism has been proposed for the 7-dehydration step based on the conservation in secondary structure and site-directed mutagenesis of the key active site amino acids. Tyr30 acts as a general acid withdrawing electron density from the 3-oxo group. This shift in electron density is hypothesized to make the 6ß-hydrogen labile for removal by the general base histidine 83 (His83) (assisted by Asp35). His83 is thought to donate its hydrogen to the 7-hydroxy forming the water-leaving group that is stabilized by Asp106. Site-directed mutagenesis based on the proposed mechanism supports the important role of the putative active site amino acids in enzyme catalysis. It is hypothesized that the baiI gene encodes a bile acid 7ß-dehydratase, because of amino acid sequence homologies between the baiE and baiI gene products.

View larger version (55K): [in this window] [in a new window]   Fig. 9. Model of the bile acid 7-dehydratase (baiE) based on structural data from scytalone dehydratase, nuclear transport factor 2, and steroid 5-isomerase. The -helices are denoted by white strands, ß-sheets are denoted by the yellow backbone, and the blue structure represents a steroid molecule modeled into the binding/active site pocket. Model kindly provided by Dr. Alexey G. Murzin (Cambridge University).

View larger version (15K): [in this window] [in a new window]   Fig. 10. Putative binding/active site pocket of bile acid 7-dehydratase. Putative active site amino acid residues are shown in relation to the bile acid substrate. See text for discussion of the proposed catalytic mechanism.

The benefits of 7/ß-dehydroxylation to the bacterium

	SECONDARY BILE ACIDS AND DISEASE

TOP ABSTRACT INTRODUCTION THE ENTEROHEPATIC CIRCULATION OF... DECONJUGATION OF BILE SALTS MICROBIAL BILE ACID... THE BIOCHEMISTRY AND MOLECULAR... SECONDARY BILE ACIDS AND... DISCUSSION REFERENCES

 
In humans, DCA accumulates in the bile acid pool to high levels in some individuals. An increase in DCA in the bile acid pool is associated with a decrease in CDCA (Fig. 11). Unlike rodents, the human liver cannot 7-hydroxylate DCA, forming CA. Hence, under normal physiological conditions, there is no metabolic pathway for removing DCA from the bile acid pool in humans. The amount of DCA in the bile acid pool is a function of at least three variables: 1) the rate of formation and absorption of DCA through the colon (input) (132); 2) colonic transit time (133); and 3) colonic pH (134).

View larger version (25K): [in this window] [in a new window]   Fig. 11. Relationship between the percentage of CDCA and DCA in bile of patients at McGuire VA Hospital (Richmond, VA) (P. B. Hylemon et al., unpublished data).

DCA and LCA have been linked to colon carcinogenesis in a number of laboratory animal models and human epidemiological studies (for reviews, see 5, 138). Most animal studies conclude that DCA is a promoter of carcinogenesis (139–142). However, some researchers argue that bile acids may cause DNA damage and act as carcinogens in humans (138). Higher levels of DCA are found in the blood of colon cancer patients compared with control patients (98, 143). Moreover, DCA is a logical candidate for promoting colon carcinogenesis for the following reasons: 1) it is found in fecal water in high concentrations (>100 µM) (138); 2) it can cross biological membranes via passive diffusion; and 3) it can activate mammalian cell signaling pathways that are known to be involved in promoting carcinogenesis. In this regard, cell signaling pathways activated by DCA in mammalian epithelial cells include protein kinase C (144), ERK1/2 via the epidermal growth factor receptor (101, 145, 146), ß-catenin (147), and Jun-N-terminal kinase 1 and 2 (JNK1/2) (148). Secondary bile acids have been shown to cause apoptosis in colonic epithelial cells, and high concentrations of DCA and LCA in stool may promote carcinogenesis by exerting selective pressure for the emergence of epithelial cell mutants that are resistant to apoptosis (e.g., via loss of p53) (138). LCA has been found to be an excellent activator of the vitamin D receptor (149, 150). Activation of this receptor in intestinal epithelial cells activates genes that metabolize LCA (150). This may be a protective mechanism that evolved to limit LCA toxicity to intestinal epithelial cells.

	DISCUSSION

TOP ABSTRACT INTRODUCTION THE ENTEROHEPATIC CIRCULATION OF... DECONJUGATION OF BILE SALTS MICROBIAL BILE ACID... THE BIOCHEMISTRY AND MOLECULAR... SECONDARY BILE ACIDS AND... DISCUSSION REFERENCES

 
Bile salt metabolism is a widespread and fundamental property of the gastrointestinal microflora encompassing the most commonly isolated species of intestinal bacteria, including but not limited to the genera Bacteroides, Clostridium, Lactobacillus, Bifidobacterium, Eubacterium, and Escherichia. However, our current understanding of the intestinal microbiology of bile salt modifications is limited to cultivated species. Discovering novel genes in the gut microbiome (collective genomes of the gastrointestinal flora) encoding BSHs, HSDHs, and enzymes involved in the 7/ß-dehydroxylation pathway through molecular techniques will facilitate a much greater understanding of the diversity and complexity of these reactions in the human colon. Techniques such as PCR-denaturing gradient gel electrophoresis can be used to measure the diversity of organisms based on specific phylogenetic markers, such as 16S rDNA, functional genes, and potentially bile salt-modifying enzymes (151, 152). Measuring the true diversity of bile salt-modifying bacteria is crucial in studying the relationship between the levels and activities of these bacteria and disease risk.

Determining the conditions in which secondary bile acids are formed in significant quantities and retained in the enterohepatic circulation of certain individuals is suggested to be important in the etiology of cholesterol gallstone disease and colon cancer. Because secondary bile acids are formed exclusively through bacterial enzymatic reactions, the study of microbes capable of bile acid 7/ß-dehydroxylation is important in understanding these chronic GI illnesses. The goal of such research is to find ways to block the source of secondary bile acid production. Long-term use of antibiotics to prevent 7-dehydroxylation of bile acids would be impractical. The design of pharmaceuticals to block the 7-dehydroxylation pathway is a possibility. However, this approach requires targeting microbial enzymes and runs the risk of eventual drug resistance, as with antibiotics. Alternatively, reducing secondary bile acid production may be achieved by administering specialized CA-accumulating probiotic bacteria (153). Studies with bifidobacteria and lactobacilli isolated from human feces have shown their ability to assimilate CA spontaneously in vitro (153, 154). The mechanism for CA uptake in lactic acid bacteria appears to be diffusion of a hydrophobic weak acid through the membrane via the transmembrane proton motive force (153, 154). The higher intracellular pH causes the bile acids to become trapped as a result of ionization.

The use of specific bacteria as "drugs" to treat chronic GI illnesses caused in part by other intestinal bacteria certainly has potential, although rigorous studies are needed to demonstrate the effectiveness of such therapies. Overall, clinical trials using probiotics to solve specific health disorders have met with mixed results. Discrepancies between studies are attributable in part to different methodologies, choice of probiotic strains, colony-forming units administered per day, and patient characteristics. One particular variable that would have to be addressed when determining bile acid assimilation by lactic acid bacteria in clinical trials is viability in vivo after passage through the gastric juice and bile. A bacterium must be alive to create a membrane potential capable of accumulating bile acids. Targeted delivery of probiotic bacteria to the intestine in microencapsulated form has shown promise in improving viability in the presence of gastric conditions and bile (155, 156). Another issue is whether the introduction of billions of probiotic bacteria to the small bowel will have an effect on bile acid input into the colon. Significant bile salt hydrolysis proximal to the terminal ileum reduces the efficiency of bile salt uptake through high-affinity transport, allowing enhanced excretion of bile acids in feces. This principle is behind attempts to decrease serum cholesterol using probiotics with bile salt hydrolytic activity (157–159). Thus, the choice of probiotic delivery mechanisms is important in addressing issues of bacterial viability and in preventing increased bile salt hydrolysis proximal to the terminal ileum. The potential impact of probiotic bacteria in reducing secondary bile acid formation in the human colon by sequestering bile acids would be greatly reduced if these same bacteria cause an increase in bile acid input into the large intestine greater than their capacity for sequestering bile acids.

	ACKNOWLEDGMENTS

 
The authors acknowledge Dr. Alexey G. Murzin of the Centre for Protein Engineering (Cambridge University) for computer modeling a three-dimensional structure of the baiE gene. The authors also thank Mikyung Kang for graphic assistance with several figures. The authors are indebted to Elaine Studer and Drs. Douglas M. Heuman, William M. Pandak, James E. Wells, Darrell H. Mallonee, and Gregorio Gil for their constructive comments and advice during the preparation of the manuscript. Finally, the authors thank the reviewers for their valuable suggestions, which have improved this article. This work was supported by a Grant from the National Institutes of Health (PO1DK38030).

Submitted on October 11, 2005
Revised on November 17, 2005

	REFERENCES

TOP ABSTRACT INTRODUCTION THE ENTEROHEPATIC CIRCULATION OF... DECONJUGATION OF BILE SALTS MICROBIAL BILE ACID... THE BIOCHEMISTRY AND MOLECULAR... SECONDARY BILE ACIDS AND... DISCUSSION REFERENCES

1. Eckburg, P. B., E. M. Bik, C. N. Bernstein, E. Purdom, L. Dethlefsen, M. Sargent, S. R. Gill, K. E. Nelson, and D. A. Relman. 2005. Diversity of the human intestinal flora. Science. 308: 1635–1638.[Abstract/Free Full Text]

2. Savage, D. C. 1977. Microbial ecology of the gastrointestinal tract. Annu. Rev. Nutr. 31: 107–133.

3. Whiteman, W. B., D. C. Coleman, and W. J. Wiebe. 1998. Prokaryotes: the unseen majority. Proc. Natl. Acad. Sci. USA. 95: 6578–6583.[Abstract/Free Full Text]

4. Wilson, M. 2005. Microbial Inhabitants of Humans. Cambridge University Press, Cambridge, UK. 1–47, 251–313, 375–392.

5. McGarr, S. E., J. M. Ridlon, and P. B. Hylemon. 2005. Diet, anaerobic bacterial metabolism and colon cancer risk: a review of the literature. J. Clin. Gastroenterol. 39: 98–109.[Medline]

6. Vlahcevic, Z. R., D. M. Heuman, and P. B. Hylemon. 1996. Physiology and pathophysiology of enterohepatic circulation of bile acids. In Hepatology: A Textbook of Liver Disease. 3^rd edition. Vol. 1. D. Zakim and T. Boyer, editors. Saunders, Philadelphia, PA. 376–417.

7. Hofmann, A. F. 1999. The continuing importance of bile acids in liver and intestinal disease. Arch. Intern. Med. 159: 2647–2658.[Abstract/Free Full Text]

8. Cowen, A. E., M. G. Korman, A. F. Hofmann, O. W. Cass, and S. B. Coffin. 1975. Metabolism of lithocholate in healthy man. II. Enterohepatic circulation. Gastroenterology. 69: 67–76.[Medline]

9. Heijghebaert, S. M., and A. F. Hofmann. 1986. Influence of the amino acid moiety on deconjugation of bile acid amidates by cholylglycine hydrolase on human fecal cultures. J. Lipid Res. 27: 742–752.[Abstract]

10. Tanaka, H., H. Hashiba, J. Kok, and I. Mierau. 2000. Bile salt hydrolase of Bifidobacterium longum biochemical and genetic characterization. Appl. Environ. Microbiol. 66: 2502–2512.[Abstract/Free Full Text]

11. Rossocha, M., R. Schultz-Heienbrok, H. von Moeller, J. P. Coleman, and W. Saenger. 2005. Conjugated bile acid hydrolase is a tetrameric N-terminal thiol hydrolase with specific recognition of its cholyl but not of its tauryl product. Biochemistry. 44: 5739–5748.[CrossRef][Medline]

12. Elkins, C. A., S. A. Moser, and D. C. Savage. 2001. Genes encoding bile salt hydrolases and conjugated bile salt transporters in Lactobacillus johnsonii 100-100 and other Lactobacillus species. Appl. Environ. Microbiol. 147: 3403–3412.

13. Gopal-Srivastava, R., and P. B. Hylemon. 1988. Purification and characterization of bile salt hydrolase from Clostridium perfringens. J. Lipid Res. 29: 1079–1085.[Abstract]

14. Grill, J. P., F. Schneider, J. Crociani, and J. Ballongue. 1995. Purification and characterization of conjugated bile salt hydrolase from Bifidobacterium longum BB536. Appl. Environ. Microbiol. 61: 2577–2582.[Abstract/Free Full Text]

15. Coleman, J. P., and L. L. Hudson. 1995. Cloning and characterization of a conjugated bile acid hydrolase gene from Clostridium perfringens. Appl. Environ. Microbiol. 61: 2514–2520.[Abstract/Free Full Text]

16. Christiaens, H., R. J. Leer, P. H. Pouwels, and W. Verstraete. 1992. Cloning and expression of a conjugated bile acid hydrolase gene from Lactobacillus plantarum by using a direct plate assay. Appl. Environ. Microbiol. 58: 3792–3798.[Abstract/Free Full Text]

17. Elkins, C. A., and D. C. Savage. 1998. Identification of genes encoding conjugated bile salt hydrolase and transport in Lactobacillus johnsonii 100-100. J. Bacteriol. 180: 4344–4349.[Abstract/Free Full Text]

18. Kim, G. B., C. M. Miyamoto, E. A. Meighen, and B. H. Lee. 2004. Cloning and characterization of the bile salt hydrolase genes (bsh) from Bifidobacterium bifidum strains. Appl. Environ. Microbiol. 70: 5603–5612.[Abstract/Free Full Text]

19. Kim, G. B., M. Brochet, and B. H. Lee. 2005. Cloning and characterization of a bile salt hydrolase (bsh) from Bifidobacterium adolescentis. Biotechnol. Lett. 27: 817–822.[CrossRef][Medline]

20. Glaser, P., L. Frangeul, C. Buchrieser, C. Rusniok, A. Amend, F. Baquero, P. Berche, H. Bloecker, P. Brandt, T. Chakraborty, et al. 2001. Comparative genomics of Listeria species. Science. 294: 849–852.[Abstract/Free Full Text]

21. Dussurget, O., D. Cabanes, P. Dehoux, M. Lecuit, C. Buchrieser, P. Glaser, P. Cossart, and the European Listeria Genome Consortium. 2002. Listeria monocytogenes bile salt hydrolase is a PrfA-regulated virulence factor involved in the intestinal and hepatic phases of listeriosis. Mol. Microbiol. 45: 1095–1106.[CrossRef][Medline]

22. Kishinaka, M., A. Umeda, and S. Kuroki. 1994. High concentrations of conjugated bile acids inhibit bacterial growth of Clostridium perfringens and induce its extracellular cholylglycine hydrolase. Steroids. 59: 485–489.[CrossRef][Medline]

23. Elkins, C. A., and D. C. Savage. 2003. CbsT2 from Lactobacillus johnsonii 100-100 is a transport protein of the major facilitator superfamily that facilitates bile acid antiport. J. Mol. Microbiol. Biotechnol. 6: 76–87.[CrossRef][Medline]

24. Lundeen, S. G., and D. C. Savage. 1992. Multiple forms of bile salt hydrolase from Lactobacillus sp. strain 100-100. J. Bacteriol. 174: 7217–7220.[Abstract/Free Full Text]

25. Stellwag, E. J., and P. B. Hylemon. 1976. Purification and characterization of bile salt hydrolase from Bacteroides fragilis subsp. fragilis. Biochim. Biophys. Acta. 452: 165–176.[Medline]

26. De Smet, I., L. Van Hoorde, M. Vande Woestyne, H. Christiaens, and W. Verstraete. 1995. Significance of bile salt hydrolytic activities of lactobacilli. J. Appl. Bacteriol. 79: 292–301.[Medline]

27. Corzo, G., and S. E. Gilliland. 1999. Measurement of bile salt hydrolase activity from Lactobacillus acidophilus based on disappearance of conjugated bile salts. J. Dairy Sci. 82: 466–471.[Abstract]

28. De Boever, P., and W. Verstraete. 1999. Bile salt deconjugation by Lactobacillus plantarum 80 and its implication for bacterial toxicity. J. Appl. Microbiol. 87: 345–352.[CrossRef][Medline]

29. Grill, J. P., C. Cayuela, J. M. Antoine, and F. Schneider. 2000. Isolation and characterization of a Lactobacillus amylovorus mutant depleted in conjugated bile salt hydrolase activity: relation between activity and bile salt resistance. J. Appl. Microbiol. 89: 553–563.[CrossRef][Medline]

30. Tannock, G. W., M. P. Dashkevicz, and S. D. Feighner. 1989. Lactobacilli and bile salt hydrolysis in the murine intestinal tract. Appl. Environ. Microbiol. 55: 1848–1851.[Abstract/Free Full Text]

31. Flahaut, S., J. Frere, P. Boutibonnes, and Y. Auffray. 1996. Comparison of the bile salts and sodium dodecyl sulfate stress response in Enterococcus faecalis. Appl. Environ. Microbiol. 62: 2416–2420.[Abstract/Free Full Text]

32. Rince, A., Y. Le Breton, N. Verneuil, J. C. Giard, A. Hartke, and Y. Auffray. 2003. Physiological and molecular aspects of bile salt response in Enterococcus faecalis. Int. J. Food Microbiol. 88: 207–213.[CrossRef][Medline]

33. Lin, J., O. Sahin, L. O. Michel, and Q. Zhang. 2003. Critical role of multidrug efflux pump CmeABC in bile resistance and in vivo colonization of Campylobacter jejuni. Infect. Immun. 71: 4250–4259.[Abstract/Free Full Text]

34. Van Eldere, J., P. Celis, G. De Pauw, E. Lesaffre, and H. Eyssen. 1996. Tauroconjugation of cholic acid stimulates 7-dehydroxylation by fecal bacteria. Appl. Environ. Microbiol. 62: 656–661.[Abstract/Free Full Text]

35. Cook, A. M., and K. Denger. 2002. Dissimilation of the C₂ sulfonates. Arch. Microbiol. 179: 1–6.[CrossRef][Medline]

36. Lengeler, J. W., G. Drews, and H. G. Schlegel. 1999. Biology of the Prokaryotes. Blackwell Science, New York. 756–758.

37. Adamowicz, M., P. M. Kelley, and K. W. Nickerson. 1991. Detergent (sodium dodecyl sulfate) shock proteins in Escherichia coli. J. Appl. Bacteriol. 137: 229–233.

38. Laue, H., M. Friedrich, J. Ruff, and A. M. Cook. 2001. Dissimilatory sulfite reductase (desulfoviridin) of the taurine-degrading, non-sulfate-reducing bacterium Bilophila wadsworthia RZATAU contains a fused DsrB-DsrD subunit. J. Bacteriol. 183: 1727–1733.[Abstract/Free Full Text]

39. Lie, T. J., M. L. Clawson, W. Godchaux, and E. R. Leadbetter. 1999. Sulfidogenesis from 2-aminoethanesulfonate (taurine) fermentation by a morphologically unusual sulfate-reducing bacterium, Desulforhopalus singaporensis sp. nov. Appl. Environ. Microbiol. 65: 3328–3334.[Abstract/Free Full Text]

40. Christl, S. U., H. D. Eisner, G. Dusel, H. Kasper, and W. Scheppach. 1996. Antagonistic effects of sulfide and butyrate on proliferation of colonic mucosa: a potential role for these agents in the pathogenesis of ulcerative colitis. Dig. Dis. Sci. 41: 2477–2481.[CrossRef][Medline]

41. Deplancke, B., and H. R. Gaskins. 2003. Hydrogen sulfide induces serum-independent cell cycle entry in nontransformed rat intestinal epithelial cells. FASEB J. 17: 1310–1312.[Abstract/Free Full Text]

42. Levitt, M. D., J. Furne, J. Springfield, F. Suarez, and E. DeMaster. 1999. Detoxification of hydrogen sulfide and methanethiol in the cecal mucosa. J. Clin. Invest. 104: 1107–1114.[Medline]

43. Levine, J., C. J. Ellis, J. K. Furne, J. Springfield, and M. D. Levitt. 1998. Fecal hydrogen sulfide production in ulcerative colitis. Am. J. Gastroenterol. 93: 83–87.[CrossRef][Medline]

44. Rose, P., P. K. Moore, S. H. Ming, O. C. Nam, J. S. Armstrong, and M. Whiteman. 2005. Hydrogen sulfide protects colon cancer cells from chemopreventative agent ß-phenylethyl isothiocyanate induced apoptosis. World J. Gastroenterol. 11: 3990–3997.[Medline]

45. Zhang, Y., and P. Talalay. 1994. Anticarcinogenic activities of organic isothiocyanates: chemistry and mechanisms. Cancer Res. 54: 1976–1981.

46. Hardison, W. G. 1978. Hepatic taurine concentration and dietary taurine as regulators of bile acid conjugation with taurine. Gastroenterology. 75: 71–75.[Medline]

47. Sjövall, J. 1959. Dietary glycine and taurine on bile acid conjugation in man: bile acids and steroids 75. Proc. Soc. Exp. Biol. Med. 100: 676–678.[CrossRef][Medline]

48. Magee, E. A., C. J. Richardson, R. Hughes, and J. H. Cummings. 2000. Contribution of dietary protein to sulfide production in the large intestine: an in vitro and a controlled feeding study in humans. Am. J. Clin. Nutr. 72: 1488–1494.[Abstract/Free Full Text]

49. Gibson, G. R., J. H. Cummings, and G. T. Macfarlane. 1991. Growth and activities of sulphate reducing bacteria in gut contents of healthy subjects and patients with ulcerative colitis. FEMS Microbiol. Ecol. 86: 103–112.[CrossRef]

50. O'Keefe, S. D. J., M. Kidd, G. Espitalier-Noel, and P. Owira. 1999. Rarity of colon cancer in Africans is associated with low animal product consumption, not fiber. Am. J. Gastroenterol. 94: 1373–1380.[CrossRef][Medline]

51. Sutherland, J. D., and I. A. Macdonald. 1982. The metabolism of primary, 7-oxo- and 7ß-hydroxy bile acids by Clostridium absonum. J. Lipid Res. 23: 726–732.[Abstract]

52. Hirano, S., and N. Masuda. 1981. Epimerization of the 7-hydroxyl group of bile acids by the combination of two kinds of microorganisms with 7- and 7ß-hydroxysteroid dehydrogenase activity, respectively. J. Lipid Res. 22: 1060–1068.[Abstract]

53. Macdonald, I. A., Y. P. Rochon, D. M. Hutchison, and L. V. Holdeman. 1982. Formation of ursodeoxycholic acid from chenodeoxycholic acid by a 7ß-hydroxysteroid dehydrogenase-elaborating Eubacterium aerofaciens strain when co-cultured with 7-hydroxysteroid dehydrogenase-elaborating organisms. Appl. Environ. Microbiol. 44: 1187–1195.[Abstract/Free Full Text]

54. Macdonald, I. A., E. C. Meier, D. E. Mahony, and G. A. Costain. 1976. 3, 7- and 12-hydroxysteroid dehydrogenase activities from Clostridium perfringens. Biochim. Biophys. Acta. 450: 466–476.

55. Edenharder, R., A. Pfützner, and R. Hammann. 1989. Characterization of NAD-dependent 3- and 3ß-hydroxysteroid dehydrogenase and of NADP-dependent 7ß-hydroxysteroid dehydrogenase from Peptostreptococcus productus. Biochim. Biophys. Acta. 1004: 230–238.[Medline]

56. Macdonald, I. A., D. E. Mahony, J. F. Jellet, and C. E. Meier. 1977. NAD-dependent 3- and 12-hydroxysteroid dehydrogenase from Eubacterium lentum ATCC 25559. Biochim. Biophys. Acta. 489: 466–476.[Medline]

57. Macdonald, I. A., J. F. Jellet, D. E. Mahony, and L. V. Holdeman. 1979. Bile salt 3- and 12-hydroxysteroid dehydrogenases from Eubacterium lentum and related strains. Appl. Environ. Microbiol. 37: 992–1000.[Abstract/Free Full Text]

58. Mallonee, D. H., M. A. Lijewski, and P. B. Hylemon. 1995. Expression in Escherichia coli and characterization of a bile acid-inducible 3-hydroxysteroid dehydrogenase from Eubacterium sp. strain VPI 12708. Curr. Microbiol. 30: 259–263.[CrossRef][Medline]

59. Wells, J. E., and P. B. Hylemon. 2000. Identification and characterization of a bile acid 7-dehydroxylating operon in Clostridium sp. strain TO931, a highly active 7-dehydroxylating strain isolated from human feces. Appl. Environ. Microbiol. 66: 1107–1113.[Abstract/Free Full Text]

60. Skalhegg, B. A. 1974. On the 3-hydroxysteroid dehydrogenase from Pseudomonas testosteroni: purifications and properties. Eur. J. Biochem. 46: 117–125.[Medline]

61. Skalhegg, B. A. 1975. 3-Hydroxysteroid dehydrogenase from Pseudomonas testosteroni: kinetic properties with NAD and its thionicotinamide analogue. Eur. J. Biochem. 50: 603–609.[Medline]

62. Edenharder, R., M. Pfützner, and R. Hammann. 1989. NADP-dependent 3ß-, 7- and 7ß-hydroxysteroid dehydrogenase activities from a lecithinase-lipase-negative Clostridium species 25.11.c. Biochim. Biophys. Acta. 1002: 37–44.[Medline]

63. Edenharder, R., and M. Pfutzner. 1989. Partial purification and characterization of an NAD-dependent 3ß-hydroxysteroid dehydrogenase from Clostridium innocuum. Appl. Environ. Microbiol. 55: 1656–1659.[Abstract/Free Full Text]

64. Akao, T., T. Akao, M. Hattori, T. Namba, and K. Kobashi. 1987. Enzymes involved in the formation of 3ß,7ß-dihydroxy-12-oxo-5ß-cholanic acid from dehydrocholic acid by Ruminococcus sp. obtained from human intestine. Biochim. Biophys. Acta. 921: 275–280.[Medline]

65. Macdonald, I. A., D. M. Hutchison, T. P. Forrest, V. D. Bokkenheuser, J. Winter, and L. V. Holdeman. 1983. Metabolism of primary bile acids by Clostridium perfringens. J. Steroid Biochem. 18: 97–104.[CrossRef][Medline]

66. Coleman, J. P., W. B. White, M. Lijewski, and P. B. Hylemon. 1988. Nucleotide sequence and regulation of a gene involved in bile acid 7-dehydroxylation by Eubacterium sp. strain VPI 12708. J. Bacteriol. 170: 2070–2077.[Abstract/Free Full Text]

67. Gopal-Srivastava, R., D. H. Mallonee, W. B. White, and P. B. Hylemon. 1990. Multiple copies of a bile acid-inducible gene in Eubacterium sp. strain VPI 12708. J. Bacteriol. 172: 4420–4426.[Abstract/Free Full Text]

68. Hylemon, P. B., and T. L. Glass. 1983. Bile acid and cholesterol metabolism. In Human Intestinal Microflora in Health and Disease. D. J. Henteges, editor. Academic Press, New York. 189–213.

69. Baron, S. F., C. V. Franklund, and P. B. Hylemon. 1991. Cloning, sequencing, and expression of the gene coding for bile acid 7-hydroxysteroid dehydrogenase from Eubacterium sp. strain VPI 12708. J. Bacteriol. 173: 4558–4569.[Abstract/Free Full Text]

70. Coleman, J. P., L. L. Hudson, and M. J. Adams. 1994. Characterization and regulation of the NADP-linked 7-hydroxysteroid dehydrogenase gene from Clostridium sordellii. J. Bacteriol. 176: 4865–4874.[Abstract/Free Full Text]

71. Bennett, M. J., S. L. McKnight, and J. P. Coleman. 2003. Cloning and characterization of the NAD-dependent 7-hydroxysteroid dehydrogenase from Bacteroides fragilis. Curr. Microbiol. 47: 475–484.[CrossRef][Medline]

72. Warchol, M., L. Car, J. P. Grill, and F. Schneider. 2003. Metabolic changes in Clostridium absonum ATCC 27555 accompanying induction of epimerization of a primary bile acid. Curr. Microbiol. 47: 425–430.[Medline]

73. Yoshimoto, T., H. Higashi, A. Kanatani, X. Sheng Lin, H. Nagai, H. Oyama, K. Kurazono, and D. Tsuru. 1991. Cloning and sequencing of the 7-hydroxysteroid dehydrogenase gene from Escherichia coli HB101 and characterization of the expressed enzyme. J. Bacteriol. 173: 2173–2179.[Abstract/Free Full Text]

74. Sherod, J. A., and P. B. Hylemon. 1977. Partial purification and characterization of NAD-dependent 7-hydroxysteroid dehydrogenase from Bacteroides thetaiotaomicron. Biochim. Biophys. Acta. 486: 351–358.[Medline]

75. Sutherland, J. D., and C. N. Williams. 1985. Bile acid induction of 7- and 7ß-hydroxysteroid dehydrogenases in Clostridium limosum. J. Lipid Res. 26: 344–350.[Abstract]

76. Macdonald, I. A., and P. D. Roach. 1981. Bile salt induction of 7- and 7ß-hydroxysteroid dehydrogenases in Clostridium absonum. Biochim. Biophys. Acta. 665: 262–269.[Medline]

77. Macdonald, I. A., D. M. Hutchison, and T. P. Forrest. 1981. Formation of urso- and ursodeoxy-cholic acids from primary bile acids by Clostridium absonum. J. Lipid Res. 22: 458–466.[Abstract]

78. Edenharder, R., and T. Knaflic. 1981. Epimerization of chenodeoxycholic acid to ursodeoxycholic acid by human intestinal lecithinase-lipase negative clostridia. J. Lipid Res. 22: 652–658.[Abstract]

79. Hylemon, P. B., and J. A. Sherrod. 1975. Multiple forms of a 7-hydroxysteroid dehydrogenase in selected strains of Bacteroides fragilis. J. Bacteriol. 122: 418–424.[Abstract/Free Full Text]

80. Franklund, C. V., P. de Prada, and P. B. Hylemon. 1990. Purification and characterization of a microbial, NADP-dependent bile acid 7-hydroxysteroid dehydrogenase. J. Biol. Chem. 265: 9842–9849.[Abstract/Free Full Text]

81. Medici, A., P. Pedrini, E. Bianchini, G. Fantin, A. Guerrini, B. Natalini, and R. Pellicciari. 2002. 7-OH epimerization of bile acids via oxido-reduction with Xanthomonas maltophilia. Steroids. 67: 51–56.[CrossRef][Medline]

82. Macdonald, I. A., B. A. White, and P. B. Hylemon. 1983. Separation of 7- and 7ß-hydroxysteroid dehydrogenase activities from Clostridium absonum ATCC# 27555 and cellular response of this organism to bile acid inducers. J. Lipid Res. 24: 1119–1126.[Abstract]

83. Sutherland, J. D., C. N. Williams, D. M. Hutchison, and L. V. Holdeman. 1987. Oxidation of primary bile acids by a 7-hydroxysteroid dehydrogenase elaborating Clostridium bifermentans soil isolate. Can. J. Microbiol. 33: 663–669.[Medline]

84. Hirano, S., N. Masuda, H. Oda, and H. Mukai. 1981. Transformation of bile acids by Clostridium perfringens. Appl. Environ. Microbiol. 42: 394–399.[Abstract/Free Full Text]

85. Prabha, V., M. Gupta, and K. G. Gupta. 1989. Kinetic properties of 7-hydroxysteroid dehydrogenase from Escherichia coli 080. Can. J. Microbiol. 35: 1076–1080.[Medline]

86. Sutherland, J. D., L. V. Holdeman, C. N. Williams, and I. A. Macdonald. 1984. Formation of urso- and ursodeoxy-cholic acids from primary bile acids by a Clostridium limosum soil isolate. J. Lipid Res. 25: 1084–1089.[Abstract]

87. Tanaka, N., T. Nonaka, T. Tanabe, T. Yoshimoto, D. Tsuru, and Y. Mitsui. 1996. Crystal structures of the binary and ternary complexes of 7-hydroxysteroid dehydrogenase from Escherichia coli. Biochemistry. 35: 7715–7730.[CrossRef][Medline]

88. Tanabe, T., N. Tanaka, K. Uchikawa, T. Kabashima, K. Ito, T. Nonaka, Y. Mitsui, M. Tsuru, and T. Yoshimoto. 1998. Roles of the Ser146, Tyr159, and Lys163 residues in the catalytic action of 7alpha-hydroxysteroid dehydrogenase from Escherichia coli. J. Biochem. (Tokyo). 124: 634–641.[Abstract/Free Full Text]

89. Harris, J. N., and P. B. Hylemon. 1978. Partial purification and characterization of NADP-dependent 12- hydroxysteroid dehydrogenase from Clostridium leptum. Biochim. Biophys. Acta. 528: 148–157.[Medline]

90. Macdonald, I. A., J. F. Jellet, and D. E. Mahony. 1979. 12-Hydroxysteroid dehydrogenase from Clostridium group P strain C48-50 ATCC 29733: partial purification and characterization. J. Lipid Res. 37: 992–1000.

91. Edenharder, R., and J. Schneider. 1985. 12ß-Dehydrogenation of bile acids by Clostridium paraputrificum, C. tertium, and C. difficile and epimerization at carbon-12 of deoxycholic acid by cocultivation with 12-dehydrogenating Eubacterium lentum. Appl. Environ. Microbiol. 49: 964–968.[Abstract/Free Full Text]

92. Edenharder, R., and A. Pfützner. 1988. Characterization of NADP-dependent 12ß-hydroxysteroid dehydrogenase from Clostridium paraputrificum. Biochim. Biophys. Acta. 962: 362–370.[Medline]

93. Reddy, B. S. 1981. Dietary fat and its relationship to large bowel cancer. Cancer Res. 41: 3700–3705.[Abstract/Free Full Text]

94. Ali, S. S., A. Kuksis, and J. M. R. Beveridge. 1966. Excretion of bile acids by three men on a fat-free diet. Can. J. Biochem. 44: 957–969.[Medline]

95. Begley, M., C. G. M. Gahan, and C. Hill. 2005. The interaction between bacteria and bile. FEMS Microbiol. Rev. 29: 625–651.[CrossRef][Medline]

96. Armstrong, M. J., and M. C. Carey. 1982. The hydrophobic-hydrophilic balance of bile salts. Inverse correlation between reverse-phase high performance liquid chromatographic mobilities and micellar cholesterol-solubilizing capacities. J. Lipid Res. 23: 70–80.[Abstract]

97. Heuman, D. M., W. M. Pandak, P. B. Hylemon, and Z. R. Vlahcevic. 1991. Conjugates of ursodeoxycholate protect against cytotoxicity of more hydrophobic bile salts: in vitro studies in rat hepatocytes and human erythrocytes. Hepatology. 14: 920–926.[Medline]

98. Bayerdörffer, E., G. A. Mannes, T. Ochsenkühn, P. Dirschedl, B. Wiebecke, and G. Paumgartner. 1995. Unconjugated secondary bile acids in the serum of patients with colorectal adenomas. Gut. 36: 268–273.[Abstract/Free Full Text]

99. Salen, G., G. S. Tint, B. Eliav, N. Deering, and E. H. Mosbach. 1974. Increased formation of ursodeoxycholic acid in patients treated with chenodeoxycholic acid. J. Clin. Invest. 53: 612–621.[Medline]

100. Hofmann, A. F. 1995. Bile acids as drugs: principles, mechanisms of action and formulations. Ital. J. Gastroenterol. 27: 106–113.[Medline]

101. Im, E., and J. D. Martinez. 2004. Ursodeoxycholic acid (UDCA) can inhibit deoxycholic acid (DCA)-induced apoptosis via modulation of EGFR/Raf-1/ERK signaling in human colon cancer cells. J. Nutr. 134: 483–486.[Abstract/Free Full Text]

102. Stellwag, E. J., and P. B. Hylemon. 1978. Characterization of 7-dehydroxylase in Clostridium leptum. Am. J. Clin. Nutr. 31 (Suppl. 10): 243–247.

103. Ferrari, A., C. Scolastino, and L. Baretta. 1977. Activity on bile salts of a Clostridium bifermentans cell-free extract. FEBS Lett. 75: 166–168.[CrossRef][Medline]

104. Wells, J. E., F. Berr, L. A. Thomas, R. H. Dowling, and P. B. Hylemon. 2000. Isolation and characterization of cholic acid 7-dehydroxylating fecal bacteria from cholesterol gallstone patients. J. Hepatol. 32: 4–10.[CrossRef][Medline]

105. Hirano, S., R. Nakama, M. Tamaki, N. Masuda, and H. Oda. 1981. Isolation and characterization of thirteen intestinal microorganisms capable of 7-dehydroxylating bile acids. Appl. Environ. Microbiol. 41: 737–745.[Abstract/Free Full Text]

106. Wells, J. E., K. B. Williams, T. R. Whitehead, D. M. Heuman, and P. B. Hylemon. 2003. Development and application of a polymerase chain reaction assay for the detection and enumeration of bile acid 7-dehydroxylating bacteria in human feces. Clin. Chim. Acta. 331: 127–134.[CrossRef][Medline]

107. Kitahara, M., F. Takamine, T. Imamura, and Y. Benno. 2000. Assignment of Eubacterium sp. VPI 12708 and related strains with high bile acid 7-dehydroxylating activity to Clostridium scindens and proposal of Clostridium hylemonae sp. nov., isolated from human feces. Int. J. Syst. Evol. Microbiol. 50: 971–978.[Abstract]

108. Kitahara, M., F. Takamine, T. Imamura, and Y. Benno. 2001. Clostridium hiranonis sp. nov., a human intestinal bacterium with bile acid 7-dehydroxylating activity. Int. J. Syst. Evol. Microbiol. 51: 39–44.[Abstract]

109. Stellwag, E. J., and P. B. Hylemon. 1979. 7-Dehydroxylation of cholic acid and chenodeoxycholic acid by Clostridium leptum. J. Lipid Res. 20: 325–333.[Abstract]

110. Batta, A. K., G. Salen, R. Arora, S. Shefer, M. Batta, and A. Person. 1990. Side chain conjugation prevents bacterial 7-dehydroxylation of bile acids. J. Biol. Chem. 265: 10925–10928.[Abstract/Free Full Text]

111. White, B. A., R. H. Lipsky, R. J. Fricke, and P. B. Hylemon. 1980. Bile acid induction specificity of 7-dehydroxylase activity in an intestinal Eubacterium sp. Steroids. 35: 103–109.[CrossRef][Medline]

112. Schmassmann, A., H. F. Fehr, J. Locher, J. Lillienau, C. D. Schteingart, S. S. Rossi, and A. F. Hofmann. 1993. Cholylsarcosine, a new bile acid analogue: metabolism and effect on biliary secretion in humans. Gastroenterology. 104: 1171–1181.[Medline]

113. White, B. A., R. J. Fricke, and P. B. Hylemon. 1982. 7ß-Dehydroxylation of ursodeoxycholic acid by whole cells and cell extracts of the intestinal anaerobic bacterium, Eubacterium species VPI 12708. J. Lipid Res. 23: 145–153.[Abstract]

114. Samuelsson, B. 1960. On the mechanism of the biological formation of deoxycholic acid from cholic acid. J. Biol. Chem. 235: 361–366.[Free Full Text]

115. Lindstedt, S., and B. Samuelsson. 1959. Bile acids and steroids. LXXXIII. On the inter-conversion of cholic and deoxycholic acid in the rat. J. Biol. Chem. 234: 2026–2030.[Free Full Text]

116. Bergstrom, S., S. Linstedt, and B. Samuelsson. 1959. Bile acids and steroids. LXXXII. On the mechanism of deoxycholic acid formation in the rabbit. J. Biol. Chem. 234: 2022–2025.[Free Full Text]

117. Björkhem, I., K. Einarsson, P. Melone, and P. B. Hylemon. 1989. Mechanism of intestinal formation of deoxycholic acid from cholic acid in humans: evidence for a 3-oxo-⁴-steroid intermediate. J. Lipid Res. 30: 1033–1039.[Abstract]

118. Hylemon, P. B., P. D. Melone, C. V. Franklund, E. Lund, and I. Björkhem. 1991. Mechanism of intestinal 7-dehydroxylation of cholic acid: evidence that allo-deoxycholic acid is an inducible side-product. J. Lipid Res. 32: 89–95.[Abstract]

119. Paone, D. A. M., and P. B. Hylemon. 1984. HPLC purification and preparation of antibodies to cholic acid-inducible polypeptides from Eubacterium sp VPI 12708. J. Lipid Res. 25: 1343–1349.[Abstract]

120. White, B. A., A. F. Cacciapuoti, R. J. Fricke, T. R. Whitehead, E. H. Mosbach, and P. B. Hylemon. 1981. Cofactor requirements for 7-dehydroxylation of cholic and chenodeoxycholic acid in cell extracts of the intestinal anaerobic bacterium, Eubacterium species VPI 12708. J. Lipid Res. 22: 891–898.[Abstract]

121. Franklund, C. V., S. F. Baron, and P. B. Hylemon. 1993. Characterization of the baiH gene encoding a bile acid-inducible NADH:flavin oxidoreductase from Eubacterium sp. strain VPI 12708. J. Bacteriol. 175: 3002–3012.[Abstract/Free Full Text]

122. White, W. B., J. P. Coleman, and P. B. Hylemon. 1988. Molecular cloning of a gene encoding a 45,000-dalton polypeptide associated with bile acid 7-dehydroxylation in Eubacterium sp. strain VPI 12708. J. Bacteriol. 170: 611–616.[Abstract/Free Full Text]

123. Coleman, J. P., W. B. White, and P. B. Hylemon. 1987. Molecular cloning of bile acid 7-dehydroxylase from Eubacterium sp. strain VPI 12708. J. Bacteriol. 169: 1516–1521.[Abstract/Free Full Text]

124. White, W. B., C. V. Franklund, J. P. Coleman, and P. B. Hylemon. 1988. Evidence for a multigene family involved in bile acid 7-dehydroxylation in Eubacterium sp. strain VPI 12708. J. Bacteriol. 170: 4555–4561.[Abstract/Free Full Text]

125. Mallonee, D. H., J. L. Adams, and P. B. Hylemon. 1992. The bile acid-inducible baiB gene from Eubacterium sp. strain VPI 12708 encodes a bile acid-coenzyme A ligase. J. Bacteriol. 174: 2065–2071.[Abstract/Free Full Text]

126. Mallonee, D. H., and P. B. Hylemon. 1996. Sequencing and expression of a gene encoding a bile acid transporter from Eubacterium sp. strain VPI 12708. J. Bacteriol. 178: 7053–7058.[Abstract/Free Full Text]

127. Mallonee, D. H., and P. B. Hylemon. 1999. Use of a short A/T-rich cassette for enhanced expression of cloned genes in Escherichia coli. Mol. Biotechnol. 11: 27–35.[Medline]

128. Dawson, J. A., D. H. Mallonee, I. Björkem, and P. B. Hylemon. 1996. Expression and characterization of a C₂₄ bile acid 7-dehydratase from Eubacterium sp. strain VPI 12708 in Escherichia coli. J. Lipid Res. 37: 1258–1267.[Abstract]

129. Baron, S. F., and P. B. Hylemon. 1995. Expression of the bile acid-inducible NADH:flavin oxidoreductase gene of Eubacterium sp. VPI 12708 in Escherichia coli. Biochim. Biophys. Acta. 1249: 145–154.[CrossRef][Medline]

130. Ye, H. Q., D. H. Mallonee, J. E. Wells, I. Björkhem, and P. B. Hylemon. 1999. The bile acid-inducible baiF gene from Eubacterium sp. strain VPI 12708 encodes a bile acid-coenzyme A hydrolase. J. Lipid Res. 40: 17–23.[Abstract/Free Full Text]

131. Heider, J. 2001. A new family of CoA-transferases. FEBS Lett. 509: 345–349.[CrossRef][Medline]

132. Berr, F., G. A. Kullak-Ublick, G. Paumgartner, W. Munzig, and P. B. Hylemon. 1996. 7 Alpha-dehydroxylating bacteria enhance deoxycholic acid input and cholesterol saturation of bile in patients with gallstones. Gastroenterology. 111: 1611–1620.[CrossRef][Medline]

133. Dowling, R. H., M. J. Veysey, S. P. Pereira, S. H. Hussaini, L. A. Thomas, J. A. Wass, and G. M. Murphy. 1997. Role of intestinal transit in the pathogenesis of gallbladder stones. Can. J. Gastroenterol. 11: 57–64.[Medline]

134. Thomas, L. A., M. J. Veysey, G. French, P. B. Hylemon, G. M. Murphy, and R. H. Dowling. 2001. Bile acid metabolism by fresh human colonic contents: a comparison of caecal versus faecal samples. Gut. 49: 835–842.[Abstract/Free Full Text]

135. Low-Beer, T. S., and S. Nutter. 1978. Colonic bacterial activity, biliary cholesterol saturation, and pathogenesis of gallstones. Lancet. 2: 1063–1065.[Medline]

136. Marcus, S. N., and K. W. Heaton. 1988. Deoxycholic acid and the pathogenesis of gall stones. Gut. 29: 522–533.[Free Full Text]

137. Hussaini, S. H., S. P. Pereira, G. M. Murphy, and R. H. Dowling. 1995. Deoxycholic acid influences cholesterol solubilization and microcrystal nucleation time in gallbladder bile. Hepatology. 22: 1735–1744.[CrossRef][Medline]

138. Bernstein, H., C. Bernstein, C. M. Payne, K. Dvorakova, and H. Garewal. 2005. Bile acids as carcinogens in human gastrointestinal cancers. Mutat. Res. 589: 47–65.[CrossRef][Medline]

139. Reddy, B. S., T. Narasawa, J. H. Weisburger, and E. L. Wynder. 1976. Promoting effect of sodium deoxycholate on colon adenocarcinomas in germfree rats. J. Natl. Cancer Inst. 56: 441–442.[Medline]

140. Pereira, M. A., W. Wang, P. M. Kramer, and L. Tao. 2004. DNA hypomethylation induced by non-genotoxic carcinogens in mouse and rat colon. Cancer Lett. 212: 145–151.[CrossRef][Medline]

141. Narisawa, T., N. E. Magadia, J. H. Weisburger, and E. L. Wynder. 1974. Promoting effect of bile acids on colon carcinogenesis after intrarectal instillation of N-methyl-N'-nitro-N-nitrosoguanidine in rats. J. Natl. Cancer Inst. 53: 1093–1097.[Medline]

142. Zusman, I., M. Chevion, and N. Kitrosski. 1992. Effects of N'methyl-N'-nitro-N-nitrosoguanidine and deoxycholic acid on the content of free radicals in rat serum. Exp. Toxicol. Pathol. 44: 187–189.[Medline]

143. Bayerdörffer, E., G. A. Mannes, W. O. Richter, T. Ochsenkühn, B. Wiebecke, W. Kopcke, and G. Paumgartner. 1993. Increased serum deoxycholic acid levels in men with colorectal adenomas. Gastroenterology. 104: 145–151.[Medline]

144. Zhu, Y., P. Hua, S. Rafiq, E. J. Waffner, M. E. Duffey, and P. Lance. 2002. Ca²⁺ and PKC-dependent stimulation of PGE2 synthesis by deoxycholic acid in human colonic fibroblasts. Am. J. Physiol. Gastrointest. Liver Physiol. 283: G503–G510.[Abstract/Free Full Text]

145. Rao, Y. P., E. J. Studer, R. T. Stravitz, S. Gupta, L. Qiao, P. Dent, and P. B. Hylemon. 2002. Activation of the Raf-1/MEK/ERK cascade by bile acids occurs via the epidermal growth factor receptor in primary rat hepatocytes. Hepatology. 35: 307–314.[CrossRef][Medline]

146. Qiao, L., E. Studer, K. Leach, R. McKinstry, S. Gupta, R. Decker, R. Kukreja, K. Valerie, P. Nagarkatti, W. El Deiry, et al. 2001. Deoxycholic acid (DCA) causes ligand-independent activation of epidermal growth factor receptor (EGFR) and FAS receptor in primary hepatocytes: inhibition of EGFR/mitogen-activated protein kinase-signaling module enhances DCA-induced apoptosis. Mol. Biol. Cell. 12: 2629–2645.[Abstract/Free Full Text]

147. Pai, R., A. S. Tarnawski, and T. Tran. 2004. Deoxycholic acid activates beta-catenin signaling pathway and increases colon cell cancer growth and invasiveness. Mol. Biol. Cell. 15: 2156–2163.[Abstract/Free Full Text]

148. Gupta, S., R. Natarajan, S. G. Payne, E. J. Studer, S. Spiegel, P. Dent, and P. B. Hylemon. 2004. Deoxycholic acid activates the c-Jun N-terminal kinase pathway via FAS receptor activation in primary hepatocytes. Role of acidic sphingomyelinase-mediated ceramide generation in FAS receptor activation. J. Biol. Chem. 279: 5821–5828.[Abstract/Free Full Text]

149. Makishima, M., T. T. Lu, W. Xie, G. K. Whitfield, H. Domoto, R. M. Evans, M. R. Haussler, and D. J. Mangelsdorf. 2002. Vitamin D receptor as an intestinal bile acid sensor. Science. 296: 1313–1316.[Abstract/Free Full Text]

150. Adachi, R., Y. Honma, H. Masuno, K. Kawana, I. Shimomura, S. Yamada, and M. Makishima. 2005. Selective activation of vitamin D receptor by lithocholic acid acetate, a bile acid derivative. J. Lipid Res. 46: 46–57.[Abstract/Free Full Text]

151. Dar, S. A., J. G. Kuenen, and G. Muyzer. 2005. Nested PCR-denaturing gradient gel electrophoresis approach to determine the diversity of sulfate-reducing bacteria in complex microbial communities. Appl. Environ. Microbiol. 71: 2325–2330.[Abstract/Free Full Text]

152. Mai, V., and J. G. Morris, Jr. 2004. Colonic bacterial flora: changing understandings in the molecular age. J. Nutr. 134: 459–464.[Abstract/Free Full Text]

153. Kurdi, P., H. Tanaka, H. W. Van Veen, K. Asano, F. Tomita, and A. Yokota. 2003. Cholic acid accumulation and its diminution by short-chain fatty acids in bifidobacteria. Microbiology. 149: 2031–2037.[Abstract/Free Full Text]

154. Kurdi, P., H. W. van Veen, H. Tanaka, I. Mierau, W. N. Konings, G. W. Tannock, F. Tomita, and A. Yokota. 2000. Cholic acid is accumulated spontaneously, driven by membrane pH, in many lactobacilli. J. Bacteriol. 182: 6525–6528.[Abstract/Free Full Text]

155. Chandramouli, V., K. Kailasapathy, P. Peiris, and M. Jones. 2004. An improved method of microencapsulation and its evaluation to protect Lactobacillus spp. in simulated gastric conditions. J. Microbiol. Methods. 56: 27–35.[CrossRef][Medline]

156. Guerin, D., J. C. Vuillemard, and M. Subirade. 2003. Protection of bifidobacteria encapsulated in polysaccharide-protein gel beads against gastric juice and bile. J. Food Prot. 66: 2076–2084.[Medline]

157. De Smet, I., P. De Boever, and W. Verstraete. 1998. Cholesterol lowering in pigs through enhanced bacterial bile salt hydrolase activity. Br. J. Nutr. 79: 185–194.[CrossRef][Medline]

158. Hepner, G., R. Fried, S. St. Jeor, L. Fusetti, and R. Morin. 1979. Hypocholesteremic effect of yogurt and milk. Am. J. Clin. Nutr. 32: 19–24.[Abstract/Free Full Text]

159. Hlivak, P., J. Odraska, M. Ferencik, L. Ebringer, E. Jahnova, and Z. Mikes. 2005. One-year application of probiotic strain Enterococcus faecium M-74 decreases serum cholesterol levels. Bratisl. Lek. Listy. 106: 67–72.[Medline]

160. Hofmann, A. F., J. Sjövall, G. Kurz, A. Radominska, C. D. Schteingart, G. S. Tint, Z. R. Vlahcevic, and K. D. Setchell. 1992. A proposed nomenclature for bile acids. J. Lipid Res. 33: 599–604.[Abstract]

161. Reddy, B. S., and E. L. Wynder. 1977. Metabolic epidemiology of colon cancer: fecal bile acids and neutral sterols in colon cancer patients and patients with adenomatous polyps. Cancer. 39: 2533–2539.[CrossRef][Medline]

162. Paumgartner, G., and A. Stiehl. 1976. Falk Symposium 24: Bile Acid Metabolism in Health and Disease. University Park Press, Baltimore, MD. 167–172.

163. Kawamoto, K., I. Horibe, and K. Uchida. 1989. Purification and characterization of a new hydrolase for conjugated bile acids, chenodeoxycholyltaurine hydrolase, from Bacteroides vulgatus. J. Biochem. (Tokyo). 106: 1049–1053.[Abstract/Free Full Text]

164. Sue, D., K. J. Boor, and M. Wiedmann. 2003. ^B-dependent expression patterns of compatible solute transporter genes opuCA and Imo1421 and the conjugated bile salt hydrolase gene bsh in Listeria monocytogenes. Microbiology. 149: 3247–3256.[Abstract/Free Full Text]

165. Hirano, S., and N. Masuda. 1982. Characterization of NADP-dependent 7 beta-hydroxysteroid dehydrogenases from Peptostreptococcus productus and Eubacterium aerofaciens. Appl. Environ. Microbiol. 43: 1057–1063.[Abstract/Free Full Text]

166. Masuda, N., H. Oda, and H. Tanaka. 1983. Purification and characterization of NADP-dependent 7 beta-hydroxysteroid dehydrogenase from Peptostreptococcus productus strain b-52. Biochim. Biophys. Acta. 755: 65–69.[Medline]

167. Macdonald, I. A., C. N. Williams, D. E. Mahony, and W. M. Christie. 1975. NAD- and NADP-dependent 7-hydroxysteroid dehydrogenase from Bacteroides fragilis. Biochim. Biophys. Acta. 384: 12–24.[Medline]

168. Hylemon, P. B., and J. Harder. 1999. Biotransformation of monoterpenes, bile acids, and other isoprenoids in anaerobic ecosystems. FEMS Microbiol. Rev. 22: 475–488.[CrossRef]

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				A. F. Hofmann, L. R. Hagey, and M. D. Krasowski Bile salts of vertebrates: structural variation and possible evolutionary significance J. Lipid Res., February 1, 2010; 51(2): 226 - 246. [Abstract] [Full Text] [PDF]

				B. M. Owen, A. Milona, S. van Mil, P. Clements, J. Holder, M. Boudjelal, W. Cairns, M. Parker, R. White, and C. Williamson Intestinal Detoxification Limits the Activation of Hepatic Pregnane X Receptor by Lithocholic Acid Drug Metab. Dispos., January 1, 2010; 38(1): 143 - 149. [Abstract] [Full Text] [PDF]

				M. Miyata, Y. Takamatsu, H. Kuribayashi, and Y. Yamazoe Administration of Ampicillin Elevates Hepatic Primary Bile Acid Synthesis through Suppression of Ileal Fibroblast Growth Factor 15 Expression J. Pharmacol. Exp. Ther., December 1, 2009; 331(3): 1079 - 1085. [Abstract] [Full Text] [PDF]

				M. E. Merritt and J. R. Donaldson Effect of bile salts on the DNA and membrane integrity of enteric bacteria J. Med. Microbiol., December 1, 2009; 58(12): 1533 - 1541. [Abstract] [Full Text] [PDF]

				S. Nishida, J. Ozeki, and M. Makishima Modulation of Bile Acid Metabolism by 1{alpha}-Hydroxyvitamin D3 Administration in Mice Drug Metab. Dispos., October 1, 2009; 37(10): 2037 - 2044. [Abstract] [Full Text] [PDF]

				F. Fang, Y. Li, M. Bumann, E. J. Raftis, P. G. Casey, J. C. Cooney, M. A. Walsh, and P. W. O'Toole Allelic Variation of Bile Salt Hydrolase Genes in Lactobacillus salivarius Does Not Determine Bile Resistance Levels J. Bacteriol., September 15, 2009; 191(18): 5743 - 5757. [Abstract] [Full Text] [PDF]

				P. B. Hylemon, H. Zhou, W. M. Pandak, S. Ren, G. Gil, and P. Dent Bile acids as regulatory molecules J. Lipid Res., August 1, 2009; 50(8): 1509 - 1520. [Abstract] [Full Text] [PDF]

				I. Martinez, G. Wallace, C. Zhang, R. Legge, A. K. Benson, T. P. Carr, E. N. Moriyama, and J. Walter Diet-Induced Metabolic Improvements in a Hamster Model of Hypercholesterolemia Are Strongly Linked to Alterations of the Gut Microbiota Appl. Envir. Microbiol., June 15, 2009; 75(12): 4175 - 4184. [Abstract] [Full Text] [PDF]

				L. R. Hagey, G. Kakiyama, A. Muto, T. Iida, K. Mushiake, T. Goto, N. Mano, J. Goto, C. A. Oliveira, and A. F. Hofmann A new, major C27 biliary bile acid in the Red-winged tinamou (Rhynchotus rufescens):(25R)-1{beta},3{alpha},7{alpha}-trihydroxy-5{beta}-cholestan-27-oic acid J. Lipid Res., April 1, 2009; 50(4): 651 - 657. [Abstract] [Full Text] [PDF]

				W. R. Wikoff, A. T. Anfora, J. Liu, P. G. Schultz, S. A. Lesley, E. C. Peters, and G. Siuzdak Metabolomics analysis reveals large effects of gut microflora on mammalian blood metabolites PNAS, March 10, 2009; 106(10): 3698 - 3703. [Abstract] [Full Text] [PDF]

				J. A. Sorg and A. L. Sonenshein Chenodeoxycholate Is an Inhibitor of Clostridium difficile Spore Germination J. Bacteriol., February 1, 2009; 191(3): 1115 - 1117. [Abstract] [Full Text] [PDF]

				M. Ogura, S. Nishida, M. Ishizawa, K. Sakurai, M. Shimizu, S. Matsuo, S. Amano, S. Uno, and M. Makishima Vitamin D3 Modulates the Expression of Bile Acid Regulatory Genes and Represses Inflammation in Bile Duct-Ligated Mice J. Pharmacol. Exp. Ther., February 1, 2009; 328(2): 564 - 570. [Abstract] [Full Text] [PDF]

				B. W. Katona, S. Anant, D. F. Covey, and W. F. Stenson Characterization of Enantiomeric Bile Acid-induced Apoptosis in Colon Cancer Cell Lines J. Biol. Chem., January 30, 2009; 284(5): 3354 - 3364. [Abstract] [Full Text] [PDF]

				P. Lefebvre, B. Cariou, F. Lien, F. Kuipers, and B. Staels Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation Physiol Rev, January 1, 2009; 89(1): 147 - 191. [Abstract] [Full Text] [PDF]

				A. K. Deo and S. M. Bandiera Identification of Human Hepatic Cytochrome P450 Enzymes Involved in the Biotransformation of Cholic and Chenodeoxycholic Acid Drug Metab. Dispos., October 1, 2008; 36(10): 1983 - 1991. [Abstract] [Full Text] [PDF]

				B. V. Jones, M. Begley, C. Hill, C. G. M. Gahan, and J. R. Marchesi Functional and comparative metagenomic analysis of bile salt hydrolase activity in the human gut microbiome PNAS, September 9, 2008; 105(36): 13580 - 13585. [Abstract] [Full Text] [PDF]

				J. M. Lambert, R. J. Siezen, W. M. de Vos, and M. Kleerebezem Improved annotation of conjugated bile acid hydrolase superfamily members in Gram-positive bacteria Microbiology, August 1, 2008; 154(8): 2492 - 2500. [Abstract] [Full Text] [PDF]

				K. Hatakka, M. Mutanen, R. Holma, M. Saxelin, and R. Korpela Lactobacillus rhamnosus LC705 Together with Propionibacterium freudenreichii ssp shermanii JS Administered in Capsules Is Ineffective in Lowering Serum Lipids J. Am. Coll. Nutr., August 1, 2008; 27(4): 441 - 447. [Abstract] [Full Text] [PDF]

				J. M. Lambert, R. S. Bongers, W. M. de Vos, and M. Kleerebezem Functional Analysis of Four Bile Salt Hydrolase and Penicillin Acylase Family Members in Lactobacillus plantarum WCFS1 Appl. Envir. Microbiol., August 1, 2008; 74(15): 4719 - 4726. [Abstract] [Full Text] [PDF]

				J. A. Sorg and A. L. Sonenshein Bile Salts and Glycine as Cogerminants for Clostridium difficile Spores J. Bacteriol., April 1, 2008; 190(7): 2505 - 2512. [Abstract] [Full Text] [PDF]

				G. Kakiyama, H. Tamegai, T. Iida, K. Mitamura, S. Ikegawa, T. Goto, N. Mano, J. Goto, P. Holz, L. R. Hagey, et al. Isolation and chemical synthesis of a major, novel biliary bile acid in the common wombat (Vombatus ursinus): 15{alpha}-hydroxylithocholic acid J. Lipid Res., December 1, 2007; 48(12): 2682 - 2692. [Abstract] [Full Text] [PDF]

				A. Birkenmaier, J. Holert, H. Erdbrink, H. M. Moeller, A. Friemel, R. Schoenenberger, M. J.-F. Suter, J. Klebensberger, and B. Philipp Biochemical and Genetic Investigation of Initial Reactions in Aerobic Degradation of the Bile Acid Cholate in Pseudomonas sp. Strain Chol1 J. Bacteriol., October 15, 2007; 189(20): 7165 - 7173. [Abstract] [Full Text] [PDF]

				C.M. Payne, C. Weber, C. Crowley-Skillicorn, K. Dvorak, H. Bernstein, C. Bernstein, H. Holubec, B. Dvorakova, and H. Garewal Deoxycholate induces mitochondrial oxidative stress and activates NF-{kappa}B through multiple mechanisms in HCT-116 colon epithelial cells Carcinogenesis, January 1, 2007; 28(1): 215 - 222. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: R500013-JLR200v1 47/2/241    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ridlon, J. M. Articles by Hylemon, P. B. Search for Related Content PubMed PubMed Citation Articles by Ridlon, J. M. Articles by Hylemon, P. B. Social Bookmarking                      What's this?